Calcigard

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcigard

Quick Facts: Calcigard (Nifedipine)

Property Description
Active ingredient Nifedipine
Form Capsules or Tablets (Oral)
Pharmacological class Calcium channel blocker (Dihydropyridine)
Common use Anti-hypertensive and Anti-anginal agent
Origin Synthetic chemical compound

What is Calcigard and its Core Composition?

Calcigard is a prescription-only medicine whose fundamental action is derived from its active ingredient, Nifedipine. This medication is a synthetic compound used in cardiovascular therapy, presented for oral consumption as either capsules or tablets. Nifedipine is chemically identified as a dihydropyridine derivative with the molecular formula C17H18N2O6. The preparation is a single-ingredient product, offered in formulations designed for both immediate-release and controlled extended-release, differentiating its therapeutic kinetics to allow for rapid action or sustained effect.

Calcigard's Classification: A Dihydropyridine Calcium Channel Blocker

The pharmacological class of Calcigard is the Dihydropyridine subgroup of Calcium channel blockers (CCB). The drug works by selectively inhibiting the transmembrane influx of calcium ions into vascular smooth muscle cells. This mechanism establishes its function primarily as a peripheral arterial vasodilator. As a foundational first-generation dihydropyridine, Nifedipine's efficacy in lowering blood pressure is documented in decades of pharmacological studies, distinguishing its action from CCBs that target the heart's electrical system more heavily.

General Purpose: What is Calcigard Used For (High-Level Benefit)?

Calcigard is utilized generally as an Anti-hypertensive agent and an Anti-anginal agent. The core benefit stems from its ability to reduce vascular tension: by inducing widespread vasodilation, the medication helps to lower high blood pressure, making it a standard choice for patients requiring long-term vascular resistance management. The drug has an established use for the symptomatic treatment of chronic stable angina pectoris and the treatment of essential hypertension, underscoring its dual purpose in managing these common cardiovascular conditions.

What side effects are possible with Calcigard?

Possible side effects and safety information

This section describes the officially documented adverse reactions and safety characteristics of Nifedipine (Calcigard), based strictly on government regulatory documents.

Frequency-Classified Adverse Reactions

The adverse reactions are categorized by frequency, reflecting incidence rates reported to health authorities.

Classification Officially Listed Examples
Very Common (geq 1 in 10) Headache
Common (1 in 100 to < 1 in 10) Peripheral oedema, Constipation, Fatigue, Dizziness, Flushing, Nausea, Malaise
Uncommon (1 in 1,000 to < 1 in 100) Sleep disturbances, Tremor, Hypotension, Tachycardia, Rash, Anxiety

System-Organ Class Grouping

Adverse effects are formally grouped by the body system they affect in regulatory texts. Primary classes involved include Vascular/Cardiovascular Disorders, Nervous System Disorders, and Gastrointestinal Disorders.

Serious Adverse Reactions and Safety Patterns

Regulatory documents list rare but serious adverse reactions, including specific blood disorders such as Agranulocytosis or Leucopenia, and rare instances of severe allergic reactions like Angioedema. The label notes that certain vasodilatory effects, such as Flushing and Peripheral Oedema, are officially documented as more common at the start of treatment or during dose escalation. Conversely, Gingival Hyperplasia is associated with prolonged use.

Population-Specific Constraints

Safety constraints are specified for certain patient groups. Individuals with Impaired Hepatic Function may require monitoring, and the medicine is contraindicated in specific acute cardiac conditions, including Cardiogenic Shock or within four weeks of a Myocardial Infarction.

Overdose and Emergency Response

Overdose and when to seek help

An acute overexposure to Calcigard (Nifedipine) is officially documented in regulatory information as potentially leading to severe and life-threatening conditions. Immediate medical attention and contact with emergency services are required upon the suspicion or manifestation of an overdose. Hospitalization for intensive monitoring is often mandated, particularly with extended-release formulations due to the risk of delayed toxicity.

The most critical documented manifestations arise from profound cardiovascular depression. These signs include severe Hypotension (a critical drop in blood pressure), Bradycardia (abnormally slow heart rate), and Consciousness disturbance which may progress to stupor or coma. Regulatory sources note that overdose can escalate to severe, life-threatening outcomes such as Cardiogenic Shock and Asystole (cardiac arrest).

Overdose management is restricted to symptomatic and supportive treatment, as regulatory documentation explicitly states that no specific antidote is known. Officially documented supportive measures include Gastric Lavage, Activated Charcoal, and the administration of Intravenous Calcium and Vasopressors. Specific considerations regarding prolonged or intensified effects apply to patients with Hepatic impairment and the elderly due to altered drug clearance noted in regulatory guidance.

This content is strictly based on the documented overdose and emergency instructions provided in official regulatory prescribing information.

Therapeutic Uses of Calcigard

What Calcigard Treats: Main Uses and Benefits

Calcigard is commonly used in therapeutic domains that involve heightened physiological activity. It plays a role in managing conditions presenting with systemic or localized discomfort and helps address symptom clusters that may become intense or disruptive. The medicine is considered relevant for easing symptoms associated with cardiovascular conditions.

The medicine may assist with easing symptoms related to systemic imbalance, specifically in the management of Essential Hypertension. It is also applied in conditions involving episodic or fluctuating manifestations, notably for the relief of Chronic Stable Angina, Vasospastic Angina, and the symptoms of Raynaud's Phenomenon.

“The primary goal of this therapy is to support the patient during difficult episodes by easing distress and helping to maintain a sense of stability when symptoms are more noticeable.”

In these therapeutic contexts, the supportive relief contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable. It contributes to improved comfort during periods of heightened symptoms and may assist with managing symptoms that interfere with daily comfort.


Quick Fact: Relief for Vascular Tone Disorders

Category Conditions/Manifestations Benefit Focus
Primary Essential Hypertension Supports systemic stability and pressure management.
Symptomatic Stable and Vasospastic Angina Contributes to improved comfort and may assist with managing symptoms that interfere with daily comfort.
Episodic Raynaud’s Phenomenon Assists with managing symptoms that create noticeable physiological strain in the extremities.

Regulatory References

  1. European Medicines Agency (EMA) Document on Nifedipine

Eligibility and Restrictions for Use

Who can and cannot use Calcigard?

Regulatory authorities define the eligibility for Calcigard (Nifedipine) through specific contraindications and conditional use requirements. The medicine is primarily intended for adults (18 years and over) for its approved indications.


Contraindicated Populations

Use is strictly prohibited for patients with known hypersensitivity to nifedipine or other dihydropyridines, those with cardiogenic shock, unstable angina pectoris, or who have experienced a myocardial infarction within the last month. Concomitant use with the antibiotic Rifampicin is an absolute contraindication, as is use of extended-release forms in patients with severe gastrointestinal obstruction.


Age and Conditional Restrictions

  • Pediatric Use: The medicine is not recommended for children and adolescents under 18 years, as safety and efficacy have not been established.
  • Pregnancy/Lactation: Use is generally contraindicated during the first trimester of pregnancy and is not recommended while breastfeeding.
  • Organ/Cardiac Impairment: Patients with hepatic impairment or poor cardiac reserve must use the medicine with caution and require careful monitoring and possible dose adjustment. Immediate-release formulations should also be avoided in older adults.

What should I know about interactions with other medicines?

Calcigard (Nifedipine) is metabolized primarily by the cytochrome P450 enzyme CYP3A4, making its blood concentration highly susceptible to co-administered medicines that affect this enzyme.

Interacting Agents and Consequences

Interaction Type Examples of Agents Regulatory Constraint
Strong CYP3A4 Inducers Rifampicin, Rifabutin, Phenytoin, Carbamazepine, St. John’s Wort Avoid Co-administration: These drugs significantly decrease Nifedipine plasma levels (e.g., by 70%), potentially compromising its effectiveness.
CYP3A4 Inhibitors Azole antifungals (Itraconazole), Macrolide antibiotics (Erythromycin, Clarithromycin), Protease inhibitors, Fluoxetine, Cimetidine Use with Caution/Monitor: These drugs increase Nifedipine exposure, requiring close blood pressure monitoring and potential dose reduction.
Pharmacodynamic Interactions beta-Blockers and Other Antihypertensives Monitor Closely: Additive effects may cause excessive lowering of blood pressure.

Other Documented Interactions

Digoxin and Immunosuppressants: Nifedipine may increase the serum concentration of Digoxin, requiring plasma level monitoring. It also increases the plasma concentration of Tacrolimus and Cyclosporine via inhibited metabolism, which necessitates frequent therapeutic drug monitoring and dose adjustment for the immunosuppressant drug.

Dietary Constraint: Grapefruit and grapefruit juice must be avoided as they significantly increase Nifedipine plasma concentrations by inhibiting its first-pass metabolism in the gut wall, an effect that can persist for several days.

Mechanism of Action

Targeted Blockade of Vascular L-Type Calcium Channels

The drug's core action is the blockade of specific L-type voltage-gated calcium channels ( CaV1.2) found predominantly in the arterial smooth muscle cells. By occupying the dedicated dihydropyridine binding site, Calcigard prevents the influx of extracellular calcium ions ( Ca^2+). This action suppresses the cellular signal required for sustained muscle contraction, leading to vascular smooth muscle relaxation.


Decrease in Systemic Vascular Resistance and Cardiac Afterload

Interruption of the calcium-driven signal causes widespread arterial vasodilation (relaxation of the blood vessel walls), which directly leads to a decrease in systemic vascular resistance (SVR). This physiological change decreases the mechanical force the heart must generate to pump blood, lowering cardiac afterload.


Engagement of the Baroreceptor Reflex

The mechanism's rapid effect of reducing SVR can engage the body's baroreceptor reflex, a compensatory autonomic mechanism. This feedback loop can temporarily increase heart rate (Reflex Tachycardia), which partially constrains the physiological event of reduced arterial pressure caused by the primary vasodilation.

Dosage and Administration Information

How to Use Calcigard: Official Administration Guidelines

Calcigard (Nifedipine) is administered orally, and the precise dosing and schedule depend on the prescribed formulation: Immediate-Release (IR) capsules or Extended-Release (ER) tablets.

Dosing and Frequency

Formulation Frequency Initial Adult Dose Maximum Daily Dose
IR Capsules Typically 3 to 4 times daily (TID or QID) 10 mg, 3 times daily 180 mg
ER Tablets Once daily (QD) 30 mg or 60 mg, once daily 120 mg

Initial dosing for the ER tablet is usually 30 mg or 60 mg once daily, with the dosage gradually increased, or titrated, over a 7 to 14 day period to find the optimal maintenance level. This medicine is generally intended for long-term therapy.

Administration Instructions

To ensure proper delivery of the medicine, Extended-Release tablets must be swallowed whole and must not be broken, crushed, or chewed.

Instructions regarding food intake vary; while IR capsules may be taken with or without food, specific ER formulations may require administration on an empty stomach. When converting from an IR capsule to an ER tablet, the total daily dose should be switched to the nearest equivalent dose of the ER formulation for once-daily use.

Special Populations

Caution is advised in certain populations. Dose adjustment may be necessary for patients with hepatic impairment due to altered drug clearance. Furthermore, the Immediate-Release formulation is generally avoided in older adults due to a higher risk of rapid changes in blood pressure. If treatment must be stopped, the dose should be gradually decreased under supervision.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calcigard (Nifedipine)

Evidence for Use in Essential Hypertension

Research has explored Calcigard's role in the study of high blood pressure through large-scale Randomized Controlled Trials (RCTs) and multi-year cardiovascular outcome trials. These studies primarily focused on measuring changes in Systolic and Diastolic Blood Pressure (BP), as well as examining long-term patterns related to major health events. The findings from this research describe patterns observed in blood pressure measurements in the treated groups. The most substantial and consistent long-term data available is derived from trials that used extended-release (ER) formulations of the medication.

Evidence for Use in Chronic Stable Angina Pectoris

The research base related to Calcigard's evaluation in the context of stable angina (chest pain) includes both short-term controlled crossover trials and large-scale, multi-year outcome trials. Studies monitored changes in the patient's reported frequency of angina attacks and functional ability, often through measuring exercise tolerance time. Short-term studies reported patterns in the frequency of angina episodes and differences observed in measured exercise capacity. Long-term trials reported on the incidence of major cardiovascular events, noting no overall pattern of difference in event rates in the total stable angina population.

Evidence for Use in Vasospastic Disorders (Raynaud's Phenomenon)

Research related to Calcigard's evaluation in the context of Raynaud's Phenomenon is derived mainly from smaller Randomized Controlled Trials (RCTs). These studies explored how symptoms change over time by measuring patient-reported outcomes for the frequency and severity of the vasospastic attacks. Trials reported patterns in the frequency of vasospastic attacks during the observation periods. However, findings related to the severity and duration of attacks were often described as limited and variable across the existing study populations, and follow-up durations were typically short.

Key Uncertainties and Research Gaps

The primary limitation concerns the research history for the immediate-release (IR) formulations; studies evaluated potential associations between rapid physiological changes and clinical events, and long-term event data for these specific formulations is limited. Furthermore, evidence describes group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Safety Notice 001/21: Use and availability of nifedipine immediate release products in threatened pre-term labour (NSW Health Guideline excerpt referencing acute hypertension in pregnancy)

Frequently Asked Questions (FAQ)

Common questions about Calcigard (FAQ)

Q: Does Calcigard have a generic version available?

The active ingredient found in Calcigard, known as Nifedipine, is available as a generic medicine. This generic version has been approved by major regulatory bodies, such as the FDA, for use in various formulations.


Q: How long does it typically take for Calcigard to start working on blood pressure?

The time it takes for the medicine to start having a measurable effect depends on the specific formulation prescribed. Official product information indicates that Immediate-Release capsules may begin working quickly, often within 10 to 30 minutes. In contrast, the Extended-Release tablets are designed for a slower, sustained onset, typically reaching their peak effect several hours after being taken.


Q: What happens if I accidentally miss a dose of Calcigard?

According to the official patient information, if a dose is missed, a person is generally advised to take it as soon as they remember. However, if it is already close to the time for the next scheduled dose, regulatory guidance suggests skipping the missed dose entirely. Official information advises against taking double or extra doses to make up for a missed one.


Q: Is Calcigard safe to use if I have kidney issues?

Official regulatory documents advise that Calcigard is used with caution if a patient has significantly impaired renal function, which refers to issues with the kidneys. Close monitoring and a dose adjustment are typically required or considered necessary in these situations.


Q: Does Calcigard contain gluten or lactose?

The composition of Calcigard varies by formulation. Official inactive ingredient lists for some Extended-Release tablets note the presence of lactose. Information regarding gluten content is generally not a required part of the standardized labeling across all regulatory documents.


Q: Are there research studies looking at Calcigard in younger adult populations?

Regulatory product labeling states that the safety and effectiveness of the active ingredient Nifedipine have not been established in pediatric patients. This includes children and adolescents under the age of 18.


Q: Does Calcigard interact with common pain relievers like ibuprofen?

Yes, official drug interaction databases indicate that certain common pain relievers, specifically Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen, may interact with Nifedipine. This interaction is associated with a potential for increased blood pressure.


Q: How does Calcigard differ from a water pill (diuretic)?

Calcigard belongs to the class of Calcium Channel Blockers and works primarily by widening the blood vessels (vasodilation) to decrease blood pressure. This differs from a diuretic, or 'water pill,' which lowers blood pressure by increasing the body's excretion of salt and water to reduce overall fluid volume.


Q: Are there any known interactions between Calcigard and alcohol?

Yes, official regulatory guidance notes a potential interaction between the active ingredient Nifedipine and alcohol. They may have an additive effect in lowering blood pressure, which may increase the likelihood of experiencing side effects such as dizziness, lightheadedness, or fainting.


Q: What should I do if I think I am experiencing an allergic reaction to Calcigard?

Official patient safety information directs immediate medical attention if symptoms of a severe allergic reaction are experienced. These symptoms may include difficulty breathing, or swelling of the face, lips, tongue, or throat.


Q: Are there specific symptoms that require immediate medical attention while using Calcigard?

Official regulatory documents describe rare but serious adverse effects. Symptoms of such events, including signs of a severe allergic reaction (like angioedema) or certain cardiovascular symptoms, are documented as requiring immediate medical attention.


Q: Does Calcigard affect eye pressure or vision?

Blurred vision is listed as a possible adverse reaction in regulatory safety information. If a person experiences vision changes while using the drug, official information advises informing a healthcare professional.


Q: Is Calcigard a blood thinner?

Calcigard is a Calcium Channel Blocker, and its function is to widen blood vessels (vasodilation) to reduce blood pressure. It is not officially classified as a blood thinner, which refers to anticoagulant or antiplatelet agents.


Q: Can Calcigard be taken with vitamins or mineral supplements?

Official guidance suggests that multivitamins that contain minerals may potentially decrease the effects of Nifedipine. Therefore, any combination of Calcigard with mineral-containing supplements is typically reviewed by a healthcare professional.


Q: Are there differences in effectiveness between the different available strengths of Calcigard?

Yes, clinical studies examining the Extended-Release formulation show differences in effect based on strength. The research reports a dose-related decrease in systolic and diastolic blood pressure with increasing strengths (such as 30 mg, 60 mg, and 90 mg).


Q: How long after taking Calcigard should I wait before driving?

Official patient safety information advises caution when driving or operating hazardous machinery until a person knows how the medication affects them. This caution is particularly related to potential side effects such as dizziness, which may occur when starting treatment.


Q: Does Calcigard have any documented interactions with cold and flu medications?

Yes, regulatory guidance indicates that certain ingredients found in common cold and flu medicines may interact with Nifedipine. These ingredients include decongestants (like Pseudoephedrine) and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) used for pain and fever.


Q: What is the duration of action for a single dose of Calcigard?

The duration of action is related to the specific formulation. For example, the Extended-Release formulation is intended to provide a sustained effect for approximately 24 hours to support once-daily dosing. The medication’s biological half-life, which measures how long it takes for the concentration to drop by half, is documented to be around 7 hours for this formulation.


Q: Why does Calcigard need to be taken every day?

Calcigard is intended for the long-term management of chronic health conditions like high blood pressure and stable angina. To maintain the medication’s continuous therapeutic benefits in managing these conditions, official guidance indicates daily intake is necessary.


Q: Why are people who have had a recent heart attack sometimes not recommended to use Calcigard?

The medicine is not recommended for use in the period immediately following a heart attack, which is also known as a myocardial infarction. Official regulatory documents list this as a contraindication due to safety concerns within acute cardiac conditions.


Q: What is the difference between Calcigard and other 'dipine' medicines?

Calcigard is classified as a Dihydropyridine-type Calcium Channel Blocker. Its main action is to widen blood vessels (vasodilation) to manage blood pressure. This distinguishes it from other types of Calcium Channel Blockers that tend to have a greater impact on the heart’s rate and rhythm.


Q: Is it normal to feel dizzy when first starting Calcigard?

Dizziness is officially documented as a common side effect of the medicine. The widening of blood vessels, or vasodilation, which is the drug's primary action, can sometimes be more noticeable when a person first begins treatment or when the dose is increased. Therefore, experiencing dizziness early on is possible.


Q: What is the official purpose of the time-release (extended-release) versions of Calcigard?

The official purpose of the Extended-Release formulation is to achieve a controlled, slower release of the medicine into the body. This is designed to provide a more sustained and stable effect over a 24-hour period, which allows for convenient once-daily dosing.


Q: What happens when Calcigard is stopped suddenly?

Official regulatory instructions advise that if Calcigard treatment must be discontinued, the dosage is documented as being gradually decreased under medical supervision. This is done to help prevent the potential for adverse effects, such as a worsening or rebound of the underlying condition.


Q: Can women who are planning pregnancy use Calcigard?

The medicine is generally contraindicated during the first three months of pregnancy. Furthermore, regulatory documents have noted evidence of potential, reversible effects on the ability of human sperm to function (observed in laboratory studies) in some men.

How should Calcigard be stored and disposed of?

How to Store and Dispose of Calcigard (Nifedipine)

The official labeling for Calcigard requires strict adherence to documented storage and disposal rules.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).
Protection Must be protected from light and moisture to maintain stability.
Container Keep the medicine in its original container and ensure it is tightly closed.
Safety Store Calcigard out of the reach and sight of children.

Disposal Instructions

Unused or expired Calcigard must be disposed of according to local regulations. If drug take-back programs are not available, it should be disposed of in household trash by mixing it with an undesirable substance, then sealed in a container to prevent misuse. The medication must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcigard found in:

A-Z Index: